<DOC>
	<DOCNO>NCT00980330</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety tolerability different regimen TMC435 standard treatment compare standard treatment alone participants chronic , genotype 1 , hepatitis C virus ( HCV ) infection fail previous treatment pegylated interferon ( Peg-INF-alfa-2a ) ribavirin ( RBV ) .</brief_summary>
	<brief_title>A Safety Effectiveness Study TMC435 Chronic , Genotype 1 , Hepatitis C Patients Who Failed Previous Standard Treatment</brief_title>
	<detailed_description>The study randomize ( study drug assign chance ) , double-blind ( neither physician participant know name assigned drug ) , placebo-controlled Phase IIb trial TMC435 participant chronic , genotype 1 , hepatitis C virus ( HCV ) infection fail standard treatment pegylated interferon ( Peg-INF-alfa-2a ) ribavirin ( RBV ) . The study compare efficacy , tolerability safety different regimen TMC435 combine standard treatment ( Peg-INF-alfa-2a RBV ) versus standard treatment alone . The trial consist screen period maximum 6 week , 48-week treatment period , 24-week follow-up period . Participants eligible enroll trial fail respond prior course standard treatment relapse follow standard treatment . Participants randomly assign receive TMC435 standard treatment 12 week follow standard treatment ( plus placebo ) 36 week , TMC435 ( 100 mg 150 mg day ) standard treatment 24 week follow standard treatment ( plus placebo ) 24 week , TMC435 ( 100 mg 150 mg day ) standard treatment 48 week , placebo standard treatment 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Must chronic hepatitis C infection evidence liver biopsy , antihepatitis C virus ( HCV ) HCV RNA positive Must chronic hepatitis C infection ( genotype 1 ) HCV RNA level great than10000 IU/mL Patient must fail least 1 prior course peg interferon ( PegIFNalfa2a ) /ribavirin ( RBV ) therapy ( standard treatment ) Must willing use 2 effective method birth control 7 month last dose study medication Has evidence decompensated liver disease Coinfection Hepatitis C virus genotype coinfection human immunodeficiency virus ( HIV ) Has medical condition contraindication PegINF RBV therapy Have history , current medical condition could impact safety patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Peginterferon alpha-2a</keyword>
	<keyword>PegIFNalpha-2a</keyword>
	<keyword>RBV</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Placebo</keyword>
	<keyword>TMC435-TIDP16-C206</keyword>
	<keyword>TMC435-C206</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
</DOC>